This article is more than 5 years old. Information may no longer be current.
TMP-SMX effective in patients with diabetic foot infections
Click Here to Manage Email Alerts
Trimethoprim-sulfamethoxazole works well for patients with diabetic foot infections, particularly when the infection is caused by Staphylococcus aureus and beta-hemolytic streptococci, according to recently published research.
Gary E. Stein, PharmD, of Michigan State University, and colleagues published data on 18 patients with diabetic foot infections who received either standard doses of TMP-SMX or high doses of TMP-SMX or linezolid.
The researchers assayed samples for drug concentrations and used patient sera “against two strains of S. aureus and three strains of beta-hemolytic streptococci.”
Stein and colleagues concluded: “Linezolid exhibited inhibitory activity in time-kill assays against strains of S. aureus (0.45 ± 0.5 log10 colony-forming units/mL) and beta-hemolytic streptococci (2.2 ± 0.6 log10 colony-forming units /mL), while TMP/SMX exhibited bactericidal (>3 log kill) activity against all of these isolates.”
The researchers said there is a growing body of research that emphasizes nonsurgical treatment of diabetic foot infections in certain patients, and that it is appropriate to consider individual patient needs and resistance patterns before treatment.
Disclosure: Stein reports no relevant financial disclosures.
Click Here to Manage Email Alerts